Mano Horinaka

发表

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

Young Hak Kim, M. Horinaka, T. Sakai, 2023, npj Precision Oncology.

Inhibition of c-Jun N-terminal kinase signaling increased apoptosis and prevented the emergence of ALK-TKI-tolerant cells in ALK-rearranged non-small cell lung cancer.

M. Horinaka, T. Sakai, S. Yano, 2021, Cancer letters.

Metformin Causes G1-Phase Arrest via Down-Regulation of MiR-221 and Enhances TRAIL Sensitivity through DR5 Up-Regulation in Pancreatic Cancer Cells

M. Horinaka, T. Sakai, Y. Sowa, 2015, PloS one.

Clostridium butyricum MIYAIRI 588 shows antitumor effects by enhancing the release of TRAIL from neutrophils through MMP-8.

T. Miki, T. Sakai, S. Yoshikawa, 2013, International journal of oncology.

Kaempferol sensitizes colon cancer cells to TRAIL-induced apoptosis.

Tatsushi Yoshida, M. Horinaka, M. Wakada, 2008, Biochemical and biophysical research communications.

The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma

M. Taniwaki, M. Horinaka, T. Sakai, 2022, International journal of molecular sciences.

PDK1 is a potential therapeutic target against angiosarcoma cells.

M. Horinaka, T. Sakai, N. Katoh, 2015, Journal of dermatological science.

Luteolin induces apoptosis via death receptor 5 upregulation in human malignant tumor cells

T. Shiraishi, Tatsushi Yoshida, Susumu Nakata, 2005, Oncogene.

Discovery of cancer-preventive juices reactivating RB functions

M. Horinaka, Toshiyuki Sakai, M. Mutoh, 2023, Environmental health and preventive medicine.

The dietary flavonoid apigenin sensitizes malignant tumor cells to tumor necrosis factor–related apoptosis-inducing ligand

T. Shiraishi, Tatsushi Yoshida, Susumu Nakata, 2006, Molecular Cancer Therapeutics.

The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells.

M. Horinaka, T. Sakai, Toshiaki Numajiri, 2020, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.

T. Shiraishi, Tatsushi Yoshida, Susumu Nakata, 2005, Cancer research.

Genistein induces Gadd45 gene and G2/M cell cycle arrest in the DU145 human prostate cancer cell line

Tatsushi Yoshida, M. Horinaka, T. Miki, 2004, FEBS letters.

Characteristic Features in the Structure and Collagen-Binding Ability of a Thermophilic Collagenolytic Protease from the Thermophile Geobacillus collagenovorans MO-1

M. Horinaka, Kunihiko Watanabe, H. Matsui, 2006, Journal of bacteriology.

Histone deacetylase inhibitors upregulate death receptor 5/TRAIL-R2 and sensitize apoptosis induced by TRAIL/APO2-L in human malignant tumor cells

T. Shiraishi, Tatsushi Yoshida, Susumu Nakata, 2004, Oncogene.

Sodium salicylate and 5-aminosalicylic acid synergistically inhibit the growth of human colon cancer cells and mouse intestinal polyp-derived cells

M. Horinaka, S. Miyamoto, Takumi Narita, 2021, Journal of clinical biochemistry and nutrition.

ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non–Small Cell Lung Cancer

M. Horinaka, T. Sakai, S. Yano, 2020, Clinical Cancer Research.

Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells

M. Horinaka, T. Sakai, S. Yano, 2022, Cancer medicine.

Sulindac sulfone inhibits the mTORC1 pathway in colon cancer cells by directly targeting voltage-dependent anion channel 1 and 2.

M. Horinaka, T. Sakai, S. Yasuda, 2018, Biochemical and biophysical research communications.

Aclarubicin enhances tumor necrosis factor‐related apoptosis‐inducing ligand‐induced apoptosis through death receptor 5 upregulation

T. Shiraishi, Tatsushi Yoshida, Susumu Nakata, 2012, Cancer science.

Epithelial-mesenchymal transition status is a remarkable biomarker for the combination treatment with avutometinib and defactinib in KRAS-mutated non-small cell lung cancer.

H. Ono, T. Yaoi, A. Yoshimura, 2024, British journal of cancer.

The Dual RAF/MEK Inhibitor CH5126766/RO5126766 May Be a Potential Therapy for RAS-Mutated Tumor Cells

M. Horinaka, T. Sakai, N. Katoh, 2014, PloS one.

The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway

M. Horinaka, T. Sakai, T. Taguchi, 2018, Breast Cancer Research and Treatment.

Glycosylation modulates TRAIL-R1/death receptor 4 protein: different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin.

T. Shiraishi, Tatsushi Yoshida, M. Horinaka, 2007, Oncology reports.

Lactobacillus strains induce TRAIL production and facilitate natural killer activity against cancer cells

Tatsushi Yoshida, T. Sakai, A. Kishi, 2010, FEBS letters.

HER3 activation contributes toward the emergence of ALK inhibitor-tolerant cells in ALK-rearranged lung cancer with mesenchymal features

M. Horinaka, T. Sakai, Ryohei Katayama, 2022, npj Precision Oncology.

Identification of c-Met as a novel target of γ-glutamylcyclotransferase

Susumu Nakata, T. Sakai, O. Ukimura, 2023, Scientific reports.

γ-Glutamylcyclotransferase, a novel regulator of HIF-1α expression, triggers aerobic glycolysis

Susumu Nakata, M. Horinaka, T. Sakai, 2021, Cancer Gene Therapy.

Ibuprofen enhances TRAIL-induced apoptosis through DR5 upregulation.

M. Horinaka, T. Sakai, E. Otsuji, 2013, Oncology reports.

Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.

T. Shiraishi, Tatsushi Yoshida, Susumu Nakata, 2005, Cancer research.

Novel RAF/MEK inhibitor CH5126766/VS‐6766 has efficacy in combination with eribulin for the treatment of triple‐negative breast cancer

M. Horinaka, T. Sakai, E. Konishi, 2021, Cancer Science.

Myeloid zinc finger 1 mediates sulindac sulfide-induced upregulation of death receptor 5 of human colon cancer cells

Tatsushi Yoshida, M. Horinaka, T. Sakai, 2014, Scientific Reports.

Baicalein overcomes tumor necrosis factor-related apoptosis-inducing ligand resistance via two different cell-specific pathways in cancer cells but not in normal cells.

Tatsushi Yoshida, M. Horinaka, M. Wakada, 2008, Cancer research.

A novel HDAC inhibitor OBP-801 and a PI3K inhibitor LY294002 synergistically induce apoptosis via the suppression of survivin and XIAP in renal cell carcinoma.

T. Miki, T. Sakai, Takeshi Yamada, 2013, International journal of oncology.

AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.

K. Kunimasa, Shinsaku Tokuda, K. Morimoto, 2024, Cancer letters.

Citrus limonL.-Derived Nanovesicles Show an Inhibitory Effect on Cell Growth in p53-Inactivated Colorectal Cancer Cells via the Macropinocytosis Pathway

M. Horinaka, Takumi Narita, Y. Sowa, 2022, Biomedicines.

Chetomin induces degradation of XIAP and enhances TRAIL sensitivity in urogenital cancer cells.

Terukazu Nakamura, Tatsushi Yoshida, M. Horinaka, 2011, International journal of oncology.

Sulforaphane suppresses cell growth and collagen expression of keloid fibroblasts

M. Horinaka, T. Sakai, Toshiaki Numajiri, 2017, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

Histone Deacetylase Inhibitors and 15-Deoxy-Δ12,14-Prostaglandin J2 Synergistically Induce Apoptosis

M. Horinaka, M. Wakada, T. Sakai, 2010, Clinical Cancer Research.

Cancer-Cell-Selective Targeting by Arylcyclopropylamine-Vorinostat Conjugates.

M. Horinaka, Yukihiro Itoh, T. Kurohara, 2022, ACS Medicinal Chemistry Letters.